~ Un-Common Sense In An Irrational World: We Challenge the Conventional WisdomTM ~
Trethera Awarded $3 Million NIH Grant to Advance First-In-Class Drug, TRE-515, for the Treatment of Lupus
Trethera has been awarded a $3 million NIH Phase II SBIR grant to advance development of its first-in-class drug, TRE-515, for the treatment of lupus. This non-dilutive funding will enable regulatory-enabling studies in toxicology, pharmacology, and efficacy testing—critical steps toward initiating clinical trials in lupus patients. [Read the full press release here.]
About TRE-515
TRE-515 is a novel deoxycytidine kinase (dCK) inhibitor that has already demonstrated a strong safety profile and early signs of clinical benefit in an ongoing human oncology trial. With its differentiated mechanism of action, TRE-515 has the potential to reshape treatment for lupus and other autoimmune diseases—addressing an urgent need where patients have limited options today.
Investment Opportunity
For a limited time, accredited investors may participate in Trethera’s Reg D 506(c) seed round, which remains open until September 30th.
Trethera will host one final investor webinar on Tuesday, September 9th at 2 PM PT. Click this link to register for the webinar.